Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2026 | 895 | 2.090 |
Why?
|
| Methotrexate | 9 | 2026 | 350 | 1.800 |
Why?
|
| Rhabdomyosarcoma | 3 | 2025 | 231 | 1.020 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2026 | 195 | 1.020 |
Why?
|
| Neurotoxicity Syndromes | 5 | 2026 | 72 | 1.000 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.670 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1586 | 0.490 |
Why?
|
| Child | 28 | 2026 | 26341 | 0.450 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2026 | 66 | 0.430 |
Why?
|
| Wilms Tumor | 2 | 2026 | 118 | 0.390 |
Why?
|
| Bayes Theorem | 3 | 2023 | 311 | 0.370 |
Why?
|
| Adolescent | 20 | 2026 | 20987 | 0.340 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 146 | 0.340 |
Why?
|
| Child, Preschool | 15 | 2026 | 15110 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2026 | 1272 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2026 | 1336 | 0.300 |
Why?
|
| Prognosis | 7 | 2026 | 4886 | 0.280 |
Why?
|
| Infant | 11 | 2026 | 13352 | 0.260 |
Why?
|
| Re-Irradiation | 1 | 2026 | 5 | 0.240 |
Why?
|
| Endpoint Determination | 1 | 2026 | 58 | 0.240 |
Why?
|
| Induction Chemotherapy | 1 | 2026 | 64 | 0.230 |
Why?
|
| Retinoblastoma | 1 | 2026 | 87 | 0.230 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2026 | 92 | 0.220 |
Why?
|
| Retrospective Studies | 12 | 2026 | 17753 | 0.220 |
Why?
|
| Burkitt Lymphoma | 1 | 2026 | 131 | 0.220 |
Why?
|
| Testicular Neoplasms | 1 | 2026 | 112 | 0.220 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.220 |
Why?
|
| Sarcoma, Ewing | 1 | 2026 | 122 | 0.220 |
Why?
|
| Humans | 30 | 2026 | 131163 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 38 | 0.210 |
Why?
|
| Risk Factors | 6 | 2026 | 11074 | 0.210 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2026 | 157 | 0.210 |
Why?
|
| Creatinine | 2 | 2023 | 398 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 1 | 2026 | 155 | 0.210 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 50 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 1410 | 0.200 |
Why?
|
| Sarcoma, Kaposi | 1 | 2025 | 129 | 0.200 |
Why?
|
| Weight Gain | 1 | 2026 | 393 | 0.200 |
Why?
|
| Hodgkin Disease | 1 | 2026 | 307 | 0.200 |
Why?
|
| Models, Statistical | 1 | 2026 | 483 | 0.200 |
Why?
|
| Constipation | 1 | 2024 | 131 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2026 | 195 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2026 | 210 | 0.190 |
Why?
|
| Osteosarcoma | 1 | 2026 | 276 | 0.190 |
Why?
|
| von Willebrand Diseases | 1 | 2023 | 54 | 0.190 |
Why?
|
| Health Information Systems | 1 | 2022 | 34 | 0.180 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 51 | 0.180 |
Why?
|
| Warfarin | 1 | 2023 | 121 | 0.180 |
Why?
|
| Male | 17 | 2026 | 64957 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2026 | 5196 | 0.180 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 191 | 0.180 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 51 | 0.180 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2022 | 32 | 0.180 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 68 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2025 | 388 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2026 | 475 | 0.170 |
Why?
|
| Neoplasms | 2 | 2026 | 3016 | 0.170 |
Why?
|
| Female | 16 | 2026 | 70963 | 0.160 |
Why?
|
| Survival Rate | 4 | 2026 | 2114 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2026 | 1717 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2023 | 487 | 0.150 |
Why?
|
| Malawi | 3 | 2026 | 348 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 339 | 0.140 |
Why?
|
| Young Adult | 7 | 2026 | 10103 | 0.140 |
Why?
|
| Catheter Ablation | 1 | 2022 | 324 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 421 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 104 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2024 | 722 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 259 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1319 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 182 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2019 | 190 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1280 | 0.110 |
Why?
|
| Age Factors | 1 | 2021 | 2825 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 530 | 0.100 |
Why?
|
| Thrombosis | 1 | 2019 | 499 | 0.100 |
Why?
|
| HIV Infections | 1 | 2026 | 2049 | 0.100 |
Why?
|
| Incidence | 3 | 2026 | 3360 | 0.090 |
Why?
|
| Mutation | 1 | 2025 | 6099 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2026 | 1216 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2026 | 1246 | 0.080 |
Why?
|
| Anticoagulants | 2 | 2024 | 605 | 0.070 |
Why?
|
| Ethiopia | 1 | 2026 | 23 | 0.060 |
Why?
|
| Uganda | 1 | 2026 | 85 | 0.060 |
Why?
|
| Platelet Count | 1 | 2026 | 139 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 28 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2024 | 152 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 201 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 44 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 104 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 64 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 78 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 48 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 286 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2023 | 158 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 105 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1489 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 387 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 960 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 589 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1287 | 0.040 |
Why?
|
| Heart Rate | 1 | 2022 | 577 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 464 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 191 | 0.030 |
Why?
|
| Texas | 1 | 2026 | 3686 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 216 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2026 | 6459 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5063 | 0.030 |
Why?
|
| Adult | 2 | 2026 | 31282 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1882 | 0.020 |
Why?
|
| Echocardiography | 1 | 2019 | 1125 | 0.020 |
Why?
|
| Time Factors | 1 | 2022 | 6196 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3763 | 0.020 |
Why?
|
| United States | 1 | 2022 | 12072 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 12936 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8635 | 0.010 |
Why?
|